Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy

被引:80
|
作者
Chen, Haijun [1 ]
Yang, Zhengduo [2 ]
Ding, Chunyong [1 ]
Chu, Lili [2 ]
Zhang, Yusong [2 ]
Terry, Kristin [2 ]
Liu, Huiling [1 ]
Shen, Qiang [2 ]
Zhou, Jia [1 ]
机构
[1] Univ Texas Med Branch, Dept Pharmacol & Toxicol, Chem Biol Program, Galveston, TX 77555 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA
关键词
Fragment-based drug design; Anticancer agents; Drug discovery; STAT3; Breast cancer; SMALL-MOLECULE INHIBITOR; SIGNAL TRANSDUCER; TRANSCRIPTION; 3; ANTITUMOR-ACTIVITY; GENE-REGULATION; CELL-GROWTH; DISCOVERY; ACTIVATOR; APOPTOSIS; TARGETS;
D O I
10.1016/j.ejmech.2013.01.023
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug design (FBDD) is a promising approach for the generation of lead molecules with enhanced activity and especially drug-like properties against therapeutic targets. Herein, we report the fragment-based drug design, systematic chemical synthesis and pharmacological evaluation of novel scaffolds as potent anticancer agents by utilizing six privileged fragments from known STAT3 inhibitors. Several new molecules such as compounds 5, 12, and 19 that may act as advanced chemical leads have been identified. The most potent compound 5 (HJC0123) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. Furthermore, compound 5 significantly suppressed estrogen receptor (ER)negative breast cancer MDA-MB-231 xenograft tumor growth in vivo (p.o.), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:498 / 507
页数:10
相关论文
共 43 条
  • [41] A novel tin based hydroxamic acid complex induces apoptosis through redox imbalance and targets Stat3/JNK1/MMP axis to overcome drug resistance in cancer
    Banerjee, Kaushik
    Choudhuri, Soumitra Kumar
    FREE RADICAL RESEARCH, 2021, 55 (9-10) : 1018 - 1035
  • [42] Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design
    Sabat, Mark
    Dougan, Douglas R.
    Knight, Beverly
    Lawson, J. David
    Scorah, Nicholas
    Smith, Christopher R.
    Taylor, Ewan R.
    Phong Vu
    Wyrick, Corey
    Wang, Haixia
    Balakrishna, Deepika
    Hixon, Mark
    Madakamutil, Loui
    McConn, Donavon
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (17) : 12893 - 12902
  • [43] Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design (vol 64, pg 12893, 2021)
    Sabat, Mark
    Dougan, Douglas R.
    Ermolieff, Jacques
    Halkowycz, Petro
    Knight, Beverly
    Lawson, J. David
    Scorah, Nicholas
    Smith, Christopher R.
    Taylor, Ewan R.
    Vu, Phong
    Wyrick, Corey
    Wang, Haixia
    Balakrishna, Deepika
    Hixon, Mark
    Madakamutil, Loui
    McConn, Donavon
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (21) : 16318 - 16318